Attovia Therapeutics, Inc. (NASDAQ:ATTO) Receives Consensus Recommendation of “Moderate Buy” from Brokerages

Attovia Therapeutics, Inc. (NASDAQ:ATTO) has been assigned an average recommendation of “Moderate Buy” from the six research firms that are covering the company, MarketBeat reports. One research analyst has rated the stock with a hold recommendation and five have given a buy recommendation to the company. The average twelve-month target price among analysts that have covered the stock in the last year is $42.20.

ATTO has been the topic of a number of research reports. Morgan Stanley initiated coverage on shares of Attovia Therapeutics in a report on Monday, August 31st. They issued an “overweight” rating and a $39.00 price target on the stock. Leerink Partners started coverage on shares of Attovia Therapeutics in a report on Monday, August 31st. They set an “outperform” rating and a $52.00 price objective for the company. Citigroup started coverage on Attovia Therapeutics in a research report on Monday, August 31st. They set a “buy” rating and a $30.00 price objective for the company. Lifesci Capital began coverage on Attovia Therapeutics in a research report on Monday, August 31st. They issued an “outperform” rating and a $45.00 target price on the stock. Finally, Zacks Research raised Attovia Therapeutics to a “hold” rating in a research note on Friday, September 4th.

Insider Buying and Selling at Attovia Therapeutics

In other news, major shareholder Life Sciences Xi L.P. Frazier bought 588,235 shares of the stock in a transaction dated Thursday, August 6th. The stock was purchased at an average cost of $17.00 per share, for a total transaction of $9,999,995.00. Following the transaction, the insider owned 6,154,213 shares of the company’s stock, valued at $104,621,621. The trade was a 10.57% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, major shareholder Goldman Sachs Group Inc bought 500,000 shares of the stock in a transaction dated Thursday, August 6th. The shares were purchased at an average price of $17.00 per share, with a total value of $8,500,000.00. Following the completion of the transaction, the insider directly owned 3,020,632 shares in the company, valued at approximately $51,350,744. The trade was a 19.84% increase in their position. The disclosure for this purchase is available in the SEC filing. Over the last ninety days, insiders bought 2,740,587 shares of company stock worth $47,269,979.

Attovia Therapeutics Price Performance

Shares of ATTO opened at $23.66 on Wednesday. Attovia Therapeutics has a 1 year low of $16.15 and a 1 year high of $28.00.

Attovia Therapeutics (NASDAQ:ATTO) last released its earnings results on Wednesday, September 2nd. The company reported ($4.88) EPS for the quarter. The firm had revenue of $0.45 million for the quarter. Sell-side analysts expect that Attovia Therapeutics will post -4.06 EPS for the current fiscal year.

About Attovia Therapeutics

Attovia Therapeutics, Inc (NASDAQ: ATTO) is a clinical-stage biopharmaceutical company developing antibody-based medicines for inflammatory and immune-mediated diseases. The company’s research is focused on creating differentiated biologic therapies intended to address significant unmet medical needs.

Attovia uses proprietary antibody-engineering technologies to discover and develop therapeutic candidates, including multispecific antibodies designed to modulate disease-related biological pathways.